Q4 2025 Jaguar Health Inc Earnings Call Transcript
Key Points
- Jaguar Health Inc (JAGX) reported a 5% increase in net revenue for Q4 2025 compared to Q3 2025, reaching approximately $3.2 million.
- The company secured a transformative US out-license agreement with Future Pak for Mytesi, providing $18 million upfront, with $16 million already received.
- Jaguar Health Inc (JAGX) continues to manufacture Crofelemer, turning it into a profit center by selling it to Future Pak.
- The company is in late-stage clinical development for rare disease intestinal failure indications, with promising data showing reduction in parenteral support needs by up to 37%.
- Jaguar Health Inc (JAGX) aims to file a new drug application for MVID by 2027, targeting a market opportunity estimated at $8 billion by 2023.
- Total net revenue for Q4 2025 decreased by approximately 8% compared to Q4 2024.
- Loss from operations increased significantly by $15.1 million from 2024 to 2025.
- Net loss attributable to common shareholders rose by approximately $15.1 million from 2024 to 2025.
- Prescription volume for Mytesi decreased by approximately 12.2% in Q4 2025 compared to the same period last year.
- The company faces challenges in achieving regulatory approval for its new drug applications, with a target NDA filing not expected until 2027.
Greetings, and welcome to Jaguar Health investor webcast. (Operator Instructions)
Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on current available information and management's current assumptions, expectations and projections about future events.
While management believes its assumptions, expectations and projections are reasonable in the view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
